Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 12/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.52 |
| ▸ | KLK7 | P49862 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585099 | 1.00 | HDAC2 (0.76) | HDAC2LMNAHDAC8HDAC3HDAC6 | |
| SCHEMBL3591282 | 0.99 | HDAC2 (0.77) | HDAC2LMNAHDAC8HDAC3HDAC6 | |
| SCHEMBL3578415 | 0.99 | HDAC2 (0.77) | HDAC2LMNAHDAC8HDAC3HDAC6 | |
| SCHEMBL8153169 | 0.89 | HDAC2 (0.76) | HDAC2LMNAHDAC8HDAC3HDAC6 | |
| SCHEMBL8143763 | 0.86 | HDAC2 (1.00) | HDAC2HDAC8HDAC3HDAC6HDAC1 | |
| SCHEMBL8155259 | 0.86 | HDAC2 (1.00) | HDAC2HDAC8HDAC3HDAC6HDAC1 | |
| SCHEMBL8149017 | 0.86 | HDAC2 (1.00) | HDAC2HDAC8HDAC3HDAC6HDAC1 | |
| SCHEMBL3590788 | 0.86 | HDAC2 (0.77) | HDAC2LMNAHDAC8HDAC3HDAC6 | |
| SCHEMBL8156566 | 0.86 | HDAC2 (0.74) | HDAC2LMNAHDAC8HDAC3HDAC6 | |
| SCHEMBL8149008 | 0.85 | HDAC2 (1.00) | HDAC2HDAC8HDAC3HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-06 | — | — | US | disclosed |
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | HDAC3, HCCS, CCNH | HDAC2 27/4885LMNA 3032/4885HDAC8 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.